Consolidated results for Q3 of the fiscal year ending December 2026 remained in deficit. Revenue was 123,507 thousand yen, operating loss was -1,329,199 thousand yen, and net loss was -1,219,888 thousand yen. R&D expenses were 557,766 thousand yen and general & administrative expenses were 832,951 thousand yen. Cash and cash equivalents were approx. 29,256,294 thousand yen, and total liabilities were approx. 4,147,795 thousand USD equivalent. Ongoing clinical trials include ALS, diabetes-related NAFLD, CCA, etc., with planned data releases and topline announcements.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4875","jir_company_name":"MediciNova, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4875-20261113-02.pdf","jir_short_summary":"Consolidated results for Q3 of the fiscal year ending December 2026 remained in deficit. Revenue was 123,507 thousand yen, operating loss was -1,329,199 thousand yen, and net loss was -1,219,888 thousand yen. R&D expenses were 557,766 thousand yen and general & administrative expenses were 832,951 thousand yen. Cash and cash equivalents were approx. 29,256,294 thousand yen, and total liabilities were approx. 4,147,795 thousand USD equivalent. Ongoing clinical trials include ALS, diabetes-related NAFLD, CCA, etc., with planned data releases and topline announcements.","jir_summary":"### Overview of Results\nFor Q3 of the fiscal year ending December 2026, revenue was 123,507 thousand yen, operating loss was -1,329,199 thousand yen, and net loss was -1,219,888 thousand yen. Research and development expenses were 557,766 thousand yen and general and administrative expenses were 832,951 thousand yen, reflecting a continued cost structure weighted toward R&D and administrative spending. Cash and cash equivalents remain substantial at approximately 29,256,294 thousand yen.\n\n### R&D Progress and Outlook\nMultiple clinical trials centered on ALS are ongoing. Several data disclosures have been announced, including COMBAT-ALS (Phase 2b\/3), SEANOBI-ALS, the MN-166 (ibudilast) related Expanded Access Program, and topline results for MN-001-NATG-202 for type 2 diabetes-related indications. Final evaluations and related results are expected to be disclosed around February 2027.","jir_financial_highlights":"Revenue: 123,507 thousand yen (Unknown)\nOperating Income: -1,329,199 thousand yen (YoY\/accumulated comparison unknown)\nNet Income Attributable to Owners of Parent: -1,219,888 thousand yen (Unknown)\nR&D Expenses: 557,766 thousand yen (No YoY change disclosed)\nGeneral & Administrative Expenses: 832,951 thousand yen (No YoY change disclosed)\nCash and Cash Equivalents: 29,256,294 thousand yen (YoY comparison unknown)","jir_category":"","jir_hashtags":"#MediciNova, #ConsideringShareBuybackInformation, #R&DProgress","jir_key_figures":"Revenue: 123,507 thousand yen\nOperating Income: -1,329,199 thousand yen\nNet Income Attributable to Owners of Parent: -1,219,888 thousand yen","jir_meta_title":"MediciNova, Inc. Q3 FY2026 Supplementary Earnings Presentation | Revenue 123,507 thousand yen, widening deficit","jir_meta_description":"Supplementary earnings presentation for MediciNova, Inc. Q3 FY2026. Summary of revenue, operating income, net income, breakdown of R&D and G&A expenses, cash balance, and status of clinical trials with upcoming data disclosure plans.","jir_og_title":"MediciNova, Inc. | Supplementary Earnings Presentation (Q3 FY2026)","jir_og_description":"Q3 FY2026 supplementary earnings presentation. Despite widening losses, R&D investment continues; latest status of ALS-centered clinical trials and planned data disclosures are explained.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2024\/12\\\",\\\"2025\/12\\\",\\\"2026\/12\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[0,0,123507]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2024\/12\\\",\\\"2025\/12\\\",\\\"2026\/12\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[-949,0,-1329199]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2024\/12\\\",\\\"2025\/12\\\",\\\"2026\/12\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[-?,-?,-2199888]}]},\\\"options\\\":{}}\"}]","ir_related_company":58821,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-150887","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n